March 10, 2020 / 12:42 PM / a month ago

BRIEF-Albireo Completes Enrollment In Phase 2 Study Of Elobixibat In NASH/NAFLD

March 10 (Reuters) - Albireo Pharma Inc:

* ALBIREO COMPLETES ENROLLMENT IN PHASE 2 STUDY OF ELOBIXIBAT IN NASH/NAFLD

* ALBIREO PHARMA INC - ON TRACK TO REPORT TOPLINE RESULTS IN MID-2020 FROM PHASE 2 CLINICAL TRIAL OF ELOBIXIBAT 5MG Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below